GET DAILY SIGNALSUFP Technologies (UFPT) Earnings Preview: Building on a Record Quarter
Key Takeaways
- UFP Technologies, Inc. (UFPT) is scheduled to report its third quarter 2026 results on Tuesday, November 3, 2026, after the market close, with a conference call on November 4 at 8:30 a.m. ET.
- Consensus estimates tracked by MarketBeat point to earnings per share (EPS) of $2.49 on revenue of roughly $166.89 million for the September 2026 quarter.
- The company enters the print after a record Q2 2026, when sales rose 15.1% to $174.0 million and adjusted EPS reached $2.92.
- Investors will focus on MedTech sales growth, gross margin trends, and progress reducing the backlog tied to the company's Illinois AJR facility.
- New robotic surgery program launches and the Dominican Republic expansion are key demand and execution themes heading into the report.
- For additional context on this ticker, explore the Major News, Today's Price Move, Price Targets, and Forecast pages.
- You can also discover related opportunities through Tickeron's Trending AI Robots.
Earnings Context and Why It Matters
UFP Technologies operates as a contract development and manufacturing organization focused on single-use and single-patient medical devices, with the medical market accounting for the bulk of its revenue. Its quarterly results offer a useful gauge of medical-device demand and the firm's ability to turn a growing pipeline into profitable production. The stock has shown notable volatility around recent reports, and the prior quarter delivered record sales, net income, and EPS. Heading into this update, investors are balancing solid MedTech demand against ongoing operational challenges and labor-related costs. How these elements resolve will influence views on near-term earnings momentum. I also checked this using Tickeron’s AI Screener to compare the stock with peers in the sector.
Earnings Expectations
For the third quarter of 2026, analysts expect UFP Technologies to post continued top-line growth. Consensus estimates tracked by MarketBeat call for EPS of approximately $2.49 on revenue of about $166.89 million, which would mark year-over-year improvement from the $154.6 million in sales reported in the third quarter of 2025. Estimates can differ across providers, so these figures should be viewed as directional.
Recent results provide helpful perspective. In Q2 2026, UFP Technologies posted record net sales of $174.0 million, up 15.1% year over year, with GAAP EPS of $2.68 and adjusted EPS of $2.92, exceeding consensus by a solid margin. In Q1 2026, sales reached $154.2 million with adjusted EPS of $2.48. These recent outperformance episodes set a higher standard for the upcoming quarter while underscoring the company's ability to deliver when execution improves.
Key metrics to examine include organic sales growth, gross margin, and the pace of backlog reduction at the AJR facility, where labor-related issues had previously delayed roughly $8 million in orders.
Market Reaction and Investor Sentiment
Sentiment ahead of the Q3 2026 report appears cautiously constructive, buoyed by the record second quarter yet tempered by questions around margin stability and operational execution. The stock has traded well below its 52-week high in recent months, reflecting uncertainty about how quickly inefficiencies at the AJR facility will ease and how ramp-up costs for new programs will affect results. A strong prior-quarter beat has drawn attention to UFP Technologies, but the market will look for signs that demand strength is converting into sustained profitability rather than being offset by transitional expenses.
Forward Outlook and Key Factors to Monitor
Beyond the headline figures, several elements will shape the company's path in coming quarters.
First, track gross margin trends. Management has noted that efficiency-related pressures should ease gradually, though some inefficiencies may linger into the fourth quarter and early 2027 as output takes priority over cost optimization. The speed of recovery will likely feature prominently on the earnings call.
Second, follow the new robotic surgery programs, which management expects to reach commercial production by year-end. These launches are positioned to contribute meaningful revenue starting in 2026 and beyond, so timing of execution matters.
Third, the Dominican Republic expansion continues to advance, with the Santiago facility now in commercial production and additional programs in qualification. Progress here influences both capacity and longer-term margin structure.
Finally, watch customer concentration and demand signals in the medical market, along with any updates on the extension or expansion of the company's largest customer contract. Together these factors outline the risk-and-reward profile after the upcoming report.
Using Tickeron’s AI Tools for Deeper Analysis
In preparing for reports like this one, I often turn to Tickeron’s AI Screener to quickly surface comparable names in the medical-device space and review technical and fundamental filters side by side. It helps narrow the field without replacing core research, and the AI-driven signals add another layer when evaluating how UFPT stacks up against peers. The platform also offers pattern recognition and trend tools that can highlight potential follow-through moves after earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UFPT in upward trend: price may jump up because it broke its lower Bollinger Band on October 30, 2026
UFPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 39 cases where UFPT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 58 cases where UFPT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The 10-day moving average for UFPT crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +3.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where UFPT advanced for three days, in 275 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 210 of 269 cases where UFPT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for UFPT moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 28 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UFPT as a result. In 60 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for UFPT turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 36 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
UFPT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UFPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. UFPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.757) is normal, around the industry mean (4.209). P/E Ratio (30.306) is within average values for comparable stocks, (1.433). Projected Growth (PEG Ratio) (5.110) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.449) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that engages in designing custom converting of foams, plastics, composites and natural fiber materials
Industry MedicalNursingServices
Advertisement